榴莲视频

Meeting Coverage >

AHA

AHA: Targeting Inflammation With Methotrexate Flops for CV Prevention

CIRT trial disappoints after CANTOS' win for the inflammatory hypothesis

AHA: Prescription Fish Oil Wins for CV Prevention

Positive findings for Vascepa in REDUCE-IT trial

AHA: Revised Lipid Guide Boosts PCSK9s, Coronary Calcium Scans

New recommendations aim to cut statins in low-risk primary prevention

AHA: Lipid Guidelines to Headline Meeting

Exercise, fish oil, Entresto in acute HF, and an anti-inflammatory also in the spotlight

AHA: Late Meals Linked to HTN, Prediabetes

Risks seen in study of Hispanic and Latino Americans

AHA: ORBITA Debate Continues

Gersh, Mehran, Block, Yeh, Chazal, Bairey Merz, Brown, Eagle weigh in

'Safer' Cigarettes Still Prove Harmful to Blood Vessels

Heat-not-burn product impacts endothelial function in animal model

AHA: Everybody Now Is a Clinical Investigator, Says Califf

Time to revolutionize clinical data gathering, ex-FDA Commissioner urges

AHA: BP Measurement in SPRINT Was All Over the Place

Did varying presence of staff during BP readings ruin a huge study?

AHA: Follow Same HTN Cutoff for Adults and Teens

But adult and pediatric hypertension guidelines differ in other respects

AHA: Evolocumab's Absolute Benefit Greater in PAD Patients

Symptomatic PAD yields bigger bang for PCSK9 big bucks

Heart Attack Fells AHA President During Annual Meeting

The AHA reports that he received a stent and is doing well

AHA: 130/80 mm Hg Is New National BP Target

Multisociety guidelines released accounting for SPRINT data

AHA: Brief NOAC Interruption Safer Than Warfarin in Afib Ablation

Fewer major bleeds than with uninterrupted warfarin in Japanese trial

AHA: CANTOS Substudy Supports Major Role of Inflammation

Large reductions in hsCRP appeared to foretell improved outcomes

AHA: For CIED Surgery, NOAC Administration Up to Clinician

Continued or interrupted therapy carried same risk of clinically significant hematoma development

AHA: Restrictive Blood Transfusion OK for Select Patients

Stricter approach deemed noninferior to liberal strategy in cardiac surgery

AHA: ACA Program Offers Mixed Results for HF Readmits

HRRP tied to less readmissions, but seems to up mortality

Sex: Odds Are It Won't Kill You

But when it is fatal, the victim is likely to be male

Trial: No Benefit for High-Dose Diuretic in Acute HF

But phase II results might not be the final word

AHA: Mixed Results For ApoA-1 Therapies

But it's still not time to write the obituary for all HDL therapies

AHA: No Pump Thrombosis With Next-Gen LVAD?

Better outcomes in HeartMate 3 trial hinged on fewer malfunctions

AHA: Lower Better for Plaque Regression with PCSK9 Drugs

No diminishing returns at very low LDL levels in GLAGOV trial

AHA: Real World TAVR Is All About Patient Selection

Intermediate risk is a moving target

Statin 'Census' Shows Major Disparities

Women, minorities treated at significantly lower rates

AHA: Healthy Lifestyle Eases Heart Impact of High Genetic Risk

Fewer adverse events, less calcification in pooled data

AHA: No Cognitive Benefit from Heart Drugs in HOPE-3

Substudy finds mental function unimproved by BP, cholesterol treatments

AHA: Long-Term Benefit in HF Patients Elusive for Novel Vasodilator

Investigational drug ularitide had no effect on mortality or clinical outcomes

AHA: Study Finds Celebrex Safe for Heart

But naproxen not as heart safe as believed

AHA: Multiple Listers for Transplants: Longer Wait, Lower Mortality

Disparity of organs by region a factor

SPRINT v. ACCORD: Which Target Will Win in Diabetes?

Not such a no-brainer, hypertension experts say

AHA: 3D Imaging May Mean Better Match for Pediatric Hearts

"Virtual transplant" could maximize use of donor hearts

AHA: Long-Acting Nitrate Flops in HFpEF

Study does not support the use of nitrates in subgroup of heart failure patients

AHA: No Excess Bleeding Risk with Dabigatran

LOS ANGELES -- Patients starting dabigatran (Pradaxa) did not have a higher risk of bleeding compared with new users of warfarin, according to a postmarketing data review by the FDA.

AHA: One or Two Drinks May Not Hurt Bypass Patients

CHICAGO -- Having an alcoholic drink does not appear to cause problems for patients following coronary artery bypass graft surgery -- but doctors warn that these patients cannot have more than one or two drinks a day.

AHA: Rivaroxaban Scores Win While Omega-3 Flops

CHICAGO -- Good news and not so good news about investigational treatments for atrial fibrillation are featured in this exclusive InFocus video report from the American Heart Association meeting.

AHA: FDA Drops Clopidogrel Bomb at AHA

ORLANDO -- The FDA has issued a public health advisory warning patients and physicians that concommitant use of clopidogrel (Plavix) and omeprazole (Prilosec and Prilosec OTC) blunts the antiplatelet effect of clopidogrel, so the combination should be avoided.

AHA: Some Statins May Disrupt Sleep

ORLANDO -- If patients taking simvastatin (Zocor) develop sleep disturbances, changing statins may be a good idea, researchers suggested here.